Rallybio Corporation - Çeyreklik Finansal İstatistikler (NASDAQ:RLYB) | MetaTrader

Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit -9.86 M-10.21 M-8.38 M-6.55 M-4.68 M -29.81 M Yatırım faaliyetlerinden elde edilen nakit -1.57 M11.08 M3.04 M29.23 M3.92 M 47.27 M Finansman faaliyetlerinden elde edilen nakit 18 K010 K06 000 16 K Serbest nakit akışı -9.86 M-10.21 M-8.38 M-6.55 M-4.68 M -29.81 M

Haberler

Rallybio’da liderlik değişikliği: Tıp direktörü ayrıldı

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Rallybio to acquire Candid Therapeutics in $505M deal

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Rallybio (NASDAQ:RLYB)

Rallybio CFO Lieber, 3.992 dolarlık hisse sattı

Lieber, Rallybio CFO, sells $3992 in shares

Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor

Rallybio announces one-for-eight reverse stock split effective Feb 6

Upcoming Stock Splits This Week (February 2 to February 6) – Stay Invested - TipRanks.com

Rallybio 6 Şubat’ta 1’e 8 ters hisse bölünmesi uygulayacak

Rallybio to implement 1-for-8 reverse stock split effective February 6

Rallybio completes first cohort dosing in RLYB116 C5 inhibitor study